PMS19 Validation of a Cost-Effectiveness MODEL in Rheumatoid Arthritis

Value in Health ◽

10.1016/j.jval.2020.08.1150 ◽

2020 ◽

Vol 23 ◽

pp. S595

Author(s):

S. Sadler ◽

I. Jacob ◽

O. Darlington ◽

E. Still ◽

J. Gordon ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Effectiveness Model

Download Full-text

Exploring Structural Uncertainty With An Open-Source Cost-Effectiveness Model For Rheumatoid Arthritis

Value in Health ◽

10.1016/j.jval.2017.08.2098 ◽

2017 ◽

Vol 20 (9) ◽

pp. A751

Author(s):

D Incerti ◽

JR Curtis ◽

M Lorenzi ◽

JP Jansen

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Open Source ◽

Structural Uncertainty ◽

Effectiveness Model

Download Full-text

How to Select the Right Cost-Effectiveness Model? A Systematic Review and Stepwise Approach for Transferring an Existing Health Economic Model for Rheumatoid Arthritis

Value in Health ◽

10.1016/j.jval.2013.08.1639 ◽

2013 ◽

Vol 16 (7) ◽

pp. A590

Author(s):

H.G.M. van Haalen ◽

A. Tran-Duy ◽

A. Boonen ◽

J.L. Severens

Keyword(s):

Rheumatoid Arthritis ◽

Systematic Review ◽

Health Economic ◽

Cost Effectiveness ◽

Economic Model ◽

Stepwise Approach ◽

Effectiveness Model ◽

Health Economic Model ◽

Download Full-text

Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis

Arthritis Care & Research ◽

10.1002/acr.22776 ◽

2016 ◽

Vol 68 (7) ◽

pp. 927-935 ◽

Author(s):

Jolanda J. Luime ◽

Leander R. Buisman ◽

Mark Oppe ◽

Johanna M. W. Hazes ◽

Maureen P. M. H. Rutten-van Mölken

Keyword(s):

Rheumatoid Arthritis ◽

At Risk ◽

Cost Effectiveness ◽

Diagnostic Tests ◽

Inflammatory Arthritis ◽

Effectiveness Model

Download Full-text

A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: Patients switching within firstline agents or to Natalizumab or Fingolimod in active RRMS

10.26226/morressier.59a3eda9d462b8028d8957ad ◽

2017 ◽

Author(s):

Tim Spelman

Keyword(s):

Cost Effectiveness ◽

Comparative Effectiveness ◽

Real World Data ◽

Effectiveness Analysis ◽

Effectiveness Model ◽

Propensity Matching ◽

Comparative Effectiveness Analysis

Download Full-text

PCN84 Preliminary Results of a Cost Effectiveness MODEL of Atezolizumab PLUS Bevacizumab in Unresectable Hepatocellular Carcinoma (HCC) in France

Value in Health ◽

10.1016/j.jval.2020.08.221 ◽

2020 ◽

Vol 23 ◽

pp. S436

Author(s):

C. Dubois de Gennes ◽

B. Mazaleyrat ◽

J. Sanchez Alvarez ◽

H. Cawston

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Preliminary Results ◽

Unresectable Hepatocellular Carcinoma ◽

Effectiveness Model

Download Full-text

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China

Rheumatology and Therapy ◽

10.1007/s40744-021-00308-w ◽

2021 ◽

Author(s):

SiNi Li ◽

JianHe Li ◽

LiuBao Peng ◽

YaMin Li ◽

XiaoMin Wan

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Severe Rheumatoid Arthritis

Download Full-text

Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening

PharmacoEconomics ◽

10.1007/s40273-021-01009-6 ◽

2021 ◽

Vol 39 (5) ◽

pp. 589-600

Author(s):

Edna Keeney ◽

Howard Thom ◽

Emma Turner ◽

Richard M. Martin ◽

Sabina Sanghera

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Cancer Screening ◽

Prostate Cancer Screening ◽

Model Application ◽

Modified Delphi ◽

Delphi Approach ◽

Effectiveness Model

Download Full-text

SAT0240 Cost effectiveness of cyclosporine (sandimmunneoral®) treatment in early severe rheumatoid arthritis: the grisar study

10.1136/annrheumdis-2001.876 ◽

2001 ◽

Author(s):

LG Mantovani ◽

A Belisari ◽

M Pisani ◽

G Pasero ◽

E Marubini ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cost Effectiveness ◽

Severe Rheumatoid Arthritis

Download Full-text

Sample size determination for a Bayesian cost-effectiveness model with structural zero costs

Communications in Statistics - Simulation and Computation ◽

10.1080/03610918.2021.1901916 ◽

2021 ◽

pp. 1-16

Author(s):

Clay King ◽

James D. Stamey

Keyword(s):

Cost Effectiveness ◽

Sample Size ◽

Sample Size Determination ◽

Size Determination ◽

Effectiveness Model

Download Full-text

Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening”

PharmacoEconomics ◽

10.1007/s40273-021-01061-2 ◽

2021 ◽

Author(s):

James F. O’Mahony

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Cancer Screening ◽

Prostate Cancer Screening ◽

Effectiveness Model ◽

Delphi Analysis

Download Full-text